Amgen (AMGN) HR SVP Derek Miller receives 3,484-share stock award

Rhea-AI Filing Summary

Amgen Inc. senior vice president of human resources Derek Miller reported an award of 3,484 shares of Amgen common stock on March 3, 2026. The shares were acquired at a stated price of $0.00 per share as a grant or similar equity award, bringing his directly held common stock to 13,744 shares after the transaction.

The reported holdings include 176 dividend equivalents granted under Amgen’s equity incentive plan, which are credited to Miller’s unvested restricted stock units and paid out in common shares on a one‑to‑one basis as those units vest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Derek

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Human Resources

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		3,484	A	$0	13,744(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 176 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Derek Miller	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Amgen (AMGN) executive Derek Miller report?

Derek Miller reported receiving 3,484 shares of Amgen common stock as an equity award. The grant was recorded at a price of $0.00 per share and increased his directly held position to 13,744 shares following the transaction.

Was Derek Miller’s Amgen (AMGN) Form 4 transaction a purchase or an award?

The Form 4 transaction for Derek Miller reflects an equity award, not an open‑market purchase. It is coded as a grant or other acquisition, indicating share-based compensation that added 3,484 Amgen common shares to his direct holdings.

How many Amgen (AMGN) shares does Derek Miller hold after this Form 4 grant?

After receiving the 3,484‑share equity award, Derek Miller directly holds 13,744 Amgen common shares. This total includes shares tied to his compensation arrangements, as disclosed in the Form 4 ownership column following the reported transaction.

What are the dividend equivalents mentioned in Derek Miller’s Amgen (AMGN) Form 4?

The filing notes 176 dividend equivalents credited under Amgen’s equity incentive plan. These track dividends on unvested restricted stock units and are paid out in Amgen common shares on a one‑to‑one basis as those restricted stock units vest over time.

Does Derek Miller’s Amgen (AMGN) Form 4 show any stock sales or dispositions?

The reported Form 4 shows only an acquisition of Amgen shares through an equity award. There are no sales or other dispositions reported in this transaction, and the net effect is an increase in Miller’s directly owned common stock position.